Kornimate/medical-research-clean huggingface dataset:
physical impairments in elderly individuals

Conditions: Aging Disorder

Summary: there are no studies in the literature reporting the dyspnea, posture, strength, physical activity, functional mobility and balance in elderly individuals. the aims of this observational study are; 1) to evaluate dyspnea, posture, strength, physical activity, functional mobility and balance in elderly individuals, 2) to reveal the relationships between these parameters of research group.

the increase in the elderly population brings with it many health problems, especially in older ages. rates of limitation and disability are increasing in elderly individuals due to chronic diseases. many of these changes negatively affect their daily living activities. with aging, respiratory muscle strength and respiratory surface area decrease in the cardiopulmonary system. respiration is negatively affected by the decrease in muscle strength. postural correctness cannot be easily achieved in elderly individuals due to deterioration in bone, muscle and joint structures. functional mobility and balance problems are observed with changes in postural control that occur with aging. there are not enough studies in the literature to clarify this issue that evalatues dyspnea, posture, strength, physical activity, functional mobility and balance in elderly individuals. therefore, the aim of our study is to evaluate dyspnea, posture, strength, physical activity, functional mobility and balance in elderly individuals. therefore, we aimed to clarify this gap.

Eligibility criteria:
inclusion criteria for elderly individuals * being 65 years or older * volunteering to participate in the study * getting a score of 23 or higher on the standardized mini mental state test exclusion criteria for elderly individuals - the participant has a cognitive, neurological or orthopedic disease that would affect the participant's ability to move independently and understand the questions.

Keywords: elderly individuals older adults dyspnea posture functional mobility balance muscle strength
the clinical effects of myofascial trigger points in disc replacement with reduction

Conditions: Temporomandibular Joint Disorders; Myofascial Trigger Point Pain; Jaw Diseases; Pain

Summary: this is a prospective, and controlled trial. 60 participants with myofascial trigger points and disc displacement with reduction and 60 participants with disc displacement with reduction will be included in the study. these two groups will be compared for clinical findings, pain severity and limitation of the temporomadibular function.

this is a prospective, and controlled trial. 60 participants with myofascial trigger points and disc displacement with reduction and 60 participants with disc displacement with reduction will be included in the study. the participants' ages will be between 18-65 years of both genders. these two groups will be compared for clinical findings with dc/tmd axis i- symptom questionnaire, pain levels in the last 1 month with dc/tmd axis ii-graded chronic pain scale, and limitation of the temporomadibular function with dc/tmd axis ii-jaw functional limitation scale-8.

Eligibility criteria:
inclusion criteria: * 18-65 years old of both genders. * presence of disc displacement with reduction with/without myofascial trigger points in master muscles. * being accepted of the participation in the study. exclusion criteria: * lack of cognitive ability to understand test instructions, illiteracy, aphasia, presence of a known psychiatric illness * refusal to participate in the study * patients under the age of 18 and over the age of 65 * having other temporomandibular joint disorders other than the diagnosis of rdd and/or myofascial trigger points

Keywords: temporomandibular joint disc displacement with reduction trigger point pain level
duloxetine role in reducing opioid consumption after thoracotomy

Conditions: Post-thoracotomy Pain

Summary: a total of 60 patients scheduled for thoracotomy with the aim of excision of pleural or lung cancer, will be randomized by the use of a computer-generated table of random numbers to receive duloxetine 60 mg orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure or a placebo pill following the same time schedule.


Eligibility criteria:
inclusion criteria * asa i, ii, and iii patients scheduled for thoracotomy for pleural or lung cancer resection. * age above 18 years \& less than 65 years. * adequate coagulation function within 30 days of surgery, defined as platelet count 100,000/ml or more, inr≤ 1.5, and partial thromboplastin time ≤40 seconds. exclusion criteria: * allergy to duloxetine or to local anesthetics. * patients with educational, psychiatric (untreated or poorly controlled schizophrenia, major depression, or bipolar disorder), or communication (language) barriers that would prevent understanding of the informed consent \& preclude accurate assessment of postoperative pain and/or ability to answer questions about pain. * patients with severe renal and/or liver disease. * history of chronic pain, long term narcotic use and/or antidepressants. * reasons for exclusion after randomization will be protocol violations or patient request. * fever, evidence of infection, or other coexisting medical conditions that would preclude epidural placement.
pulsed dye laser treatment of recent surgical scars

Conditions: Surgical Scars

Summary: hypothesis: improvement of recent surgical scars after treatment with 595nm pulsed dye laser treatments. study design: prospective single blinded within patient controlled randomised trial. recent surgical scars of at least 5cm will be divided into 2 parts and randomized. 1 part will be treated with 4 595nm pulsed dye laser treatments on a 4 weeks interval. the other part will serve as a within patient control. 1 and 6 months after the intervention both parts of the scar will be evaluated.


Eligibility criteria:
inclusion criteria: * patients with planned surgical intervention leaving a scar from at least 5 cm in an area prone to hypertrophic scarring : neck, shoulders, chest, mandibular angle and extremities * age at least 18 years old. * patient able and willing to give written informed consent exclusion criteria: * patients with planned surgical intervention on hands, feet and genital area * patients with a history of photodermatoses * patients with a history of keloids * patients with a history of adverse outcomes related to pdl
the use of computed tomography (ct) to measure skeletal muscle quantity and quality in patients receiving ecmo

Conditions: Critical Illness; Muscle Atrophy

Summary: this is a retrospective, observational study and will investigate the clinical predictive value of and change in muscle quantity and quality in critically ill patients with severe respiratory failure requiring veno-venous extracorporeal membrane oxygenation (vv-ecmo).

the use of veno-venous extra-corporeal membrane oxygenation (vv-ecmo) for severe respiratory failure - mainly hypoxaemia - has increased over recent years. similar to the general population in the intensive care unit (icu), these patients become deconditioned, severely weak (icu acquired weakness- icuaw) and require prolonged rehabilitation after disconnection from vv-ecmo. however, data regarding the magnitude of muscle wasting and recovery in this specific group is lacking. both poor muscle quantity and quality have been found to be a predictor or poor outcome. as all patients receiving vv-ecmo at our hospital will get an initial ct scan of their chest, abdomen and pelvis, these ct scans will be used to measure muscle quantity and quality of different muscle groups of the abdomen at admission and then using any follow-up ct scan performed within 10 days. in addition, the relationship between the loss of muscle over the course of vv-ecmo and perceived recovery of renal function at icu discharge will be investigated.

Eligibility criteria:
inclusion criteria: * critically ill patients with severe respiratory failure who required vv-ecmo and had one or more ct scans of their abdomen exclusion criteria: * critically ill patients with severe respiratory failure who required vv-ecmo and did not have one or more ct scans of their abdomen * critically ill patients with severe respiratory failure who required vv-ecmo who have a poor quality ct scan not analysable by the software
lifestyle changes in obese males with sexual dysfunction and tinnitus

Conditions: Obesity; Tinnitus, Subjective; Erectile Dysfunction

Summary: obese male usually complain subjective tinnitus that may affect their sexual function.

this study will enroll forty obese males with subjective tinnitus (bilateral complaint) and sexual dysfunction (erectile dysfunction) who will be divided to group i and group ii with an equal number of males within each group (n =20 for the group). all male in both groups will administer low calorie diet for 12 weeks but group i will additionally administer supervised walking training aerobic training for 45 minutes 3 times per week for 12 weeks).

Eligibility criteria:
inclusion criteria: * obese person * body mass index less than 40 kg/m2 and more than 30 kg/m2 * males with subjective tinnitus (bilateral presentation from at least 24 weeks). * males with sexual dysfunction (erectile dysfunction from at least 24 weeks) exclusion criteria: * cardiac diseased males * respiratory diseased males * hepatic, musculoskeletal, and hepatic diseased males * diabetic males
effect of intensive lipid lowering treatment compared to moderate lipid lowering treatment on endothelial function

Conditions: Endothelial Dysfunction; Atherosclerosis

Summary: the aim of this study was to measure the effect of moderate and intensive lipid-lowering treatment with rosuvastatin on the endothelial function.


Eligibility criteria:
inclusion criteria: 1. stemi 2. no prior treatment with statins exclusion criteria: 1. age below 18 or above 81 years 2. unconscious patients 3. serum creatinine \> 176μmol/l 4. total-cholesterol \> 7.0 mmol/l 5. hypothyreoidism ((tsh \> 1.5 x uln (upper limit of normal)) 6. current liver disease (alat \> 2 x uln) 7. unexplained creatine kinase \> 3 x uln 8. alcohol or drug abuse within the last five years 9. prior myopathy or serious hypersensitivity reaction caused by statins 10. women with childbearing potential who were not using chemical or mechanical contraception 11. pregnant or breastfeeding women 12. history of malignancy unless a disease-free period of more than five years was present 13. patients with abnormal lung function test (lft) 14. participation in another investigational drug study less than four weeks before enrolment in the present study 15. treatment with cyclosporine or fibrates.
phase i/ii trial of ptk787 and pemetrexed with or without cisplatin for lung cancer

Conditions: Non-Small Cell Lung Cancer and Pleural Mesothelioma

Summary: this is an open-label, two-arm, multicenter phase ia/ii dose-escalation study of ptk787 in combination with pemetrexed alone (cohort 1) or pemetrexed and cisplatin (cohort 2). this study is designed to determine the maximum tolerated dose (mtd) and dose limiting toxicity (dlt) of ptk787 when administered in combination with pemetrexed or pemetrexed and cisplatin, and to characterize the safety, tolerability, biologic activity, and pk profile of ptk787 in adult patients with advanced non-small cell lung cancers and mesotheliomas.

this is an open-label, two-arm, multicenter phase ia/ii dose-escalation study of ptk787 in combination with pemetrexed alone (cohort 1) or pemetrexed and cisplatin (cohort 2). this study is designed to determine the maximum tolerated dose (mtd) and dose limiting toxicity (dlt) of ptk787 when administered in combination with pemetrexed or pemetrexed and cisplatin, and to characterize the safety, tolerability, biologic activity, and pk profile of ptk787 in adult patients with advanced non-small cell lung cancers and mesotheliomas. in cohort 1, ptk787 will be administered orally every 12 hours on days 2-42 of a 42-day cycle. in addition, pemetrexed will be administered on days 1 and 22. in cohort 2, ptk787 will be administered orally every 12 hours on days 2-42 of a 42 day cycle. in addition, pemetrexed will be administered on days 1 and 22. thirty minutes after pemetrexed administration, cisplatin will be infused on days 1 and 22. in the current study, initially patients will be treated on cohort 1 (pemetrexed + ptk787). once an mtd determination is made on this cohort (or ptk787 has been escalated to the maximum dose of 750 mg q12h enrollment will begin on cohort 2. at the mtd dose, both cohorts will be expanded to a minimum of 20 patients to determine additional safety of the combinations.

Eligibility criteria:
inclusion criteria: * patients with advanced non-small cell lung cancers (non-squamous variety and advanced mesotheliomas * patients with advanced solid tumors who are refractory to standard treatments and/or standard treatments are not be available for the patient exclusion criteria: * non-small cell carcinoma of squamous variety * patients with uncontrolled brain metastases

Keywords: non-small cell lung cancer pleural mesothelioma
assessment of patient experience during treatment for cancer

Conditions: Carcinoma

Summary: assessing the mindset of cancer patients will help us better understand which patients are having difficulty dealing with the diagnosis and treatment that may not otherwise be fully appreciated by their physicians. by identifying such patients, we may then be able to design and implement strategies that can help improve their coping skills both during the treatment as well as after the completion of treatment. in addition to addressing physical concerns and symptoms, this approach will help address the overall emotional impact of a cancer diagnosis as more patients are living as cancer survivors.


Eligibility criteria:
inclusion criteria: * pathologically diagnosed carcinoma patients at stanford cancer center who signed the informed consent form. exclusion criteria: * patients with a prognosis of \< 6 months life expectancy
the immediate effect of combined terminal knee extension exercise with audible cues

Conditions: Muscle Weakness

Summary: typically, patients perform tke by themselves after exercise prescription. the investigators thought that a lack of attention and preferred speed of patients might not provide the best outcome. therefore, an increased effectiveness of tke is interesting for physical therapy implication. besides, adding sensory input which is audible cues or rhythm during exercise may enhance the efficacy of the exercise by increasing neuromuscular control and function. therefore, the study aimed to investigate the immediate effects of combined tke with audible cues on motor unit behavior. the researchers expect that adding rhythm from the metronome will enhance neuromuscular control which may change motor unit behavior of vm muscle. the findings of the study may have helped explain the mechanism behind the acute effects of combined tke with audible cues on vm function and their potential application in the field of physical therapy. this study aims to investigate the immediate effect of combined tke with audible cues on motor unit behavior in healthy participants and to investigate reliability of decomposition electromyography procedure during single leg squat.

a metronome will be used to provide rhythmic exercise. participants will stand with their feet in line with their shoulders as starting position and straping at the knee. exercise intensity is 60% of the 1rm weight. at the beginning of the exercise, participants will be asked to bend their knees following the pull of the resistance and exert force to straighten the knee (10 times/set and 3 sets). 180 seconds of resting will be allowed between sets.

Eligibility criteria:
inclusion criteria: * aged range between 18 and 30 years * bmi of 18.5-25 kg/m2 * male or female * lightly active or sedentary {physical activity level (pal= 1.4-1.69)} exclusion criteria: * history of serious injury or operation of lower back and lower extremities such as fracture * musculoskeletal problems of lower back and lower extremities in 6 months before the study * single-leg stance test \< 43 seconds (26). and range of weight-bearing lunge test \< 9.1 cm

Keywords: terminal knee extension exercise audible cues therapeutic exercise muscle strength
neurophysiological study of sativex in multiple sclerosis (ms) spasticity

Conditions: Multiple Sclerosis

Summary: aim of this randomized, double-blind, placebo-controlled, cross-over study is to investigate cannabinoid-induced changes in neurophysiological parameters in a group of 40 patients with secondary or primary progressive multiple sclerosis (ms).


Eligibility criteria:
inclusion criteria: * aged 18 years or above * willing and able to comply with the protocol for the duration of the study * diagnosis of secondary-progressive or primary-progressive ms from at least 12 months * relapse free from at least 3 months before screening visit * lower limb spasticity * edss from \> 3.0 and \< 6.5 * moderate to severe spasticity due to ms from at least 6 months and with stable drug treatment not able to relieve symptoms as a whole, deserving a specific add-on treatment * immunomodulatory or immunosuppressant therapies not modified during the study and 6 months before starting the study * stable doses of anti-spasticity agents from at least 2 months prior to screening visit * have given written informed consent exclusion criteria: * any concomitant disease that may cause spasticity or that could interfere with subject's spasticity * botulinum toxin injection for spasticity in the 4 months prior to screening visit * any known or suspected history of psychotic illness, alcohol or substance abuse, epilepsy, hypersensitivity to cannabinoids * significant cardiac, renal or hepatic disease * female subjects of child bearing potentials and male subjects whose partner is child bearing potential, unless willing to ensure that they or their partner use contraception during the study * female subjects who is pregnant lactating or planning pregnancy during the course of the study and for three months thereafter * sativex® smpc contraindications

Keywords: spasticity
clinical trial assessing the efficacy and safety of dendritic cell-based immunotherapy for glioblastoma

Conditions: Glioblastoma

Summary: this phase iii, multicenter, placebo-controlled clinical trial with sequential randomization is designed to evaluate the efficacy and safety of an experimental vaccine composed of hybrid dendritic cells (dcs) for the treatment of glioblastoma. conducted at the hospital das clínicas of the university of são paulo medical school (hcfmusp) and the institute of biomedical sciences of the university of são paulo (icb/usp), the study is led by professor josé alexandre marzagão barbuto. a multidisciplinary team of researchers specializing in neurosurgery, pathology, hematology, and other fields will contribute to a comprehensive approach. the trial aims to determine whether the hybrid dc vaccine can increase overall survival in adult patients with glioblastoma who have completed standard treatment, including surgery, chemotherapy, and radiotherapy. secondary objectives include evaluating progression-free survival, quality of life, immune response, and the safety of the intervention. the study will enroll 186 patients, who will be randomized into three groups: (1) a control group receiving placebo, (2) a group receiving the dc vaccine, and (3) a group receiving the dc vaccine combined with pembrolizumab.


Eligibility criteria:
inclusion criteria: * adult patients with a histological diagnosis of glioblastoma and confirmed idh status. * currently undergoing standard-of-care treatment, which includes surgery, chemotherapy, and radiotherapy. * availability of pre-treatment magnetic resonance imaging (mri). * ability to attend clinical follow-ups every 2 months. * functional performance score \> 50 at the time of study enrollment. * tumor cells capable of expansion in culture. exclusion criteria: * patients with any concomitant neoplasm (except basal cell carcinoma). * pregnant or breastfeeding individuals. * patients with significant medical or surgical conditions as determined by the study team, psychiatric disorders, or those requiring medications or treatments that could interfere with study procedures or the evaluation of the vaccine's safety and efficacy. * patients who are hiv-positive, immunosuppressed, and/or have undergone organ transplantation. * refusal or inability to provide consent, such as patients with aphasia. * participation in any experimental treatment protocols within the 6 months prior to enrollment.

Keywords: glioblastoma dendritic cell vaccine clinical trial
enmotion, embryo's natural motion

Conditions: Infertility

Summary: the purpose of the study is to determine if a dynamic embryo microenvironment impacts embryo development and reproductive potential in comparison to static culture.

the proposed research design is a prospective randomized control trial. patients with normal ovarian reserve, who would be expected to have reasonable outcomes after in vitro fertilization, will serve as the subjects. embryos from the same patient will be randomized to either static or dynamic culture. they will then be cultured to the blastocyst stage of embryo development and biopsied for preimplantation genetic screening. the best chromosomally normal embryo from each culture group will be selected and transferred to complete a double embryo transfer in a subsequent frozen embryo transfer cycle the following month.

Eligibility criteria:
inclusion criteria: * infertile women seeking in vitro fertilization treatment with aneuploidy screening * patient is eligible for a two-embryo transfer in compliance with asrm guidelines * patient able to undergo a frozen embryo transfer cycle the month following the vaginal oocyte retrieval procedure * maximum day 3 follicle-stimulating hormone level (≤12 iu/l) * anti-mullerian hormone level ≥ 1.2g/ml, tested within previous year * ≤1 prior failed ivf cycle * male partner with \>100,000 total motile spermatozoa per ejaculate (donor sperm acceptable) * body mass index ≤ 32 * antral follicle count ≥ 8 exclusion criteria: * diagnosis of endometrial insufficiency defined as a prior cycle with maximal endometrial thickness ≤ 6mm, abnormal endometrial pattern (failure to attain a trilaminar appearance), persistent endometrial fluid * use of oocyte donation * use of gestational carrier * medical contraindication to double embryo transfer * use of testicular aspiration or biopsy procedures to obtain sperm * presence of a hydrosalpinx that communicates with the endometrial cavity * any contraindications to undergoing in vitro fertilization or gonadotropin stimulation * single gene disorder requiring more detailed embryo genetic analysis

Keywords: preimplantation embryo development